Keunchil Park

Summary

Affiliation: Sungkyunkwan University
Country: Korea

Publications

  1. pmc Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    PLoS ONE 8:e64816. 2013
  2. doi request reprint The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor
    Youngwook Kim
    Medical Nano Element Development Center, Samsung Biomedical Research Institute, Seoul, Korea
    Mol Cancer Ther 11:784-91. 2012
  3. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
  4. doi request reprint ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy
    In Gyu Hwang
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Cancer 113:1379-86. 2008
  5. ncbi request reprint A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Jeeyun Lee
    Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Gu, Seoul 135 710, Korea
    Cancer Chemother Pharmacol 62:77-84. 2008
  6. ncbi request reprint Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma
    Byeong Bae Park
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea
    Invest New Drugs 26:387-92. 2008
  7. ncbi request reprint Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Ku, Seoul 135 710, Republic of Korea
    Leuk Res 31:359-64. 2007
  8. doi request reprint Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography
    Hong Kwan Kim
    Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 6:336-42. 2011
  9. ncbi request reprint Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer
    Keon Woo Park
    Division of Hematology Oncology, Department of Medicine, Dankook University Hospital, Cheonan, South Korea
    Cancer Chemother Pharmacol 59:17-21. 2007
  10. ncbi request reprint A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Byeong Bae Park
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Gu, Seoul 135 710, South Korea
    Cancer Chemother Pharmacol 60:489-94. 2007

Collaborators

Detail Information

Publications84

  1. pmc Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    PLoS ONE 8:e64816. 2013
    ..These results suggested KRAS mutations have an independent prognostic value but a limited predictive role for EGFR TKIs or cytotoxic chemotherapy in advanced NSCLC...
  2. doi request reprint The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor
    Youngwook Kim
    Medical Nano Element Development Center, Samsung Biomedical Research Institute, Seoul, Korea
    Mol Cancer Ther 11:784-91. 2012
    ..This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs...
  3. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
    ..East-Asian ethnicity is an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a higher incidence of EGFR mutations among this patient population...
  4. doi request reprint ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy
    In Gyu Hwang
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Cancer 113:1379-86. 2008
    ..The aim of this study was to evaluate the clinical implications of ERCC1 expression in stage IIIA N2-positive NSCLC patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery...
  5. ncbi request reprint A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Jeeyun Lee
    Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Gu, Seoul 135 710, Korea
    Cancer Chemother Pharmacol 62:77-84. 2008
    ..This phase II study assessed the efficacy and safety of capecitabine/cisplatin (XP) as a first-line chemotherapy in a homogenous cohort of patients with metastatic or recurrent esophageal squamous cell carcinoma...
  6. ncbi request reprint Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma
    Byeong Bae Park
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea
    Invest New Drugs 26:387-92. 2008
    ....
  7. ncbi request reprint Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Ku, Seoul 135 710, Republic of Korea
    Leuk Res 31:359-64. 2007
    ..9 months), an estimated 5-year overall survival rate was 88.9% and a 5-year disease-free survival rate was 83.1%. Primary surgical resection followed by post-operative CHOP chemotherapy showed high efficacy in intestinal DLBL patients...
  8. doi request reprint Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography
    Hong Kwan Kim
    Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 6:336-42. 2011
    ....
  9. ncbi request reprint Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer
    Keon Woo Park
    Division of Hematology Oncology, Department of Medicine, Dankook University Hospital, Cheonan, South Korea
    Cancer Chemother Pharmacol 59:17-21. 2007
    ..Therefore, we conducted a phase II study to assess the efficacy and the toxicity of a combination regimen of docetaxel plus cisplatin in patients with advanced gastric cancer who have never been treated with palliative chemotherapy...
  10. ncbi request reprint A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Byeong Bae Park
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Gu, Seoul 135 710, South Korea
    Cancer Chemother Pharmacol 60:489-94. 2007
    ..In addition, we also analyzed the correlation between CA19-9 response and clinical outcomes...
  11. ncbi request reprint Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
    Hyo Song Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, Seoul, 135 710, Korea
    Breast Cancer Res Treat 118:89-97. 2009
    ..036; hazard ratio [HR], 2.1; 95% CI 1.01-4.14).These kinetics may serve as a good predictive marker of treatment response and response duration...
  12. doi request reprint Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
    Ji Eun Uhm
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Int J Cancer 124:1457-62. 2009
    ..Further prospective studies are warranted...
  13. ncbi request reprint CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation
    Yeon Hee Park
    Department of Hematology Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Leuk Lymphoma 47:1253-9. 2006
    ..This organ-preserving combined treatment is highly effective and well tolerated for the patients with localized gastric DLBCL...
  14. ncbi request reprint Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Oncol Rep 15:1541-9. 2006
    ..The addition of curcumin or celecoxib to the IFN-alpha-pretreated A549 cells altered the IFN-alpha sensitivity of cell growth inhibition...
  15. ncbi request reprint Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer
    Kyoung Ju Kim
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Gangnam Gu, Seoul 135 710, Republic of Korea
    Lung Cancer 55:329-36. 2007
    ..68), respectively. Following CRCT and surgery, achieving ypN0 stage turned out to be a significantly favorable indicator, while the initial mediastinal lymph node extent did not, with respect to overall survival and disease-free survival...
  16. ncbi request reprint Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Sang Hoon Ji
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong Kangnam Ku, Seoul 135 710, Korea
    Jpn J Clin Oncol 35:214-7. 2005
    ..We evaluated the efficacy and tolerability of a modified biweekly irinotecan, 5-fluorouracil and leucovorin regimen (modified Douillard regimen) as the first-line therapy in patients with advanced colorectal cancer...
  17. doi request reprint Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy
    Jong Mu Sun
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Int J Radiat Oncol Biol Phys 80:655-60. 2011
    ..We evaluated whether ERCC1 expression could predict the treatment response and survival outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy...
  18. doi request reprint Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
    Kyoung Ha Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul 135 710, Republic of Korea
    Lung Cancer 68:258-63. 2010
    ..This study aimed to analyze the outcome for various treatment modalities including chemotherapy only, upfront whole brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) in NSCLC patients with asymptomatic brain metastases...
  19. doi request reprint Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma
    Jeong Il Yu
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Int J Radiat Oncol Biol Phys 78:507-12. 2010
    ..To report treatment outcomes after combined-modality therapy in patients with Stage I/II head-and-neck (HN) diffuse large B cell lymphoma (DLBL)...
  20. doi request reprint Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Myung Hee Chang
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea
    Cancer Chemother Pharmacol 64:917-24. 2009
    ..We conducted a prospective phase II trial of IrOx in patients with advanced non-small cell lung cancer to evaluate the efficacy and toxicity...
  21. doi request reprint Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes
    Ho Yun Lee
    Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, IlWon Dong, Kangnam Ku, Seoul, Korea
    Acad Radiol 19:440-5. 2012
    ....
  22. doi request reprint Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial
    Jong Mu Sun
    Department of Medicine, Samsung Medical Center, Seoul, Korea
    Cancer 118:6234-42. 2012
    ..Gefitinib was compared with pemetrexed as second-line therapy in a clinically selected population previously treated with platinum-based chemotherapy...
  23. ncbi request reprint Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer
    Se Hoon Lee
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Jpn J Clin Oncol 33:620-5. 2003
    ..We conducted a phase II trial of early concurrent CRT, starting from the very beginning of the first cycle of chemotherapy for previously untreated LSCLC...
  24. ncbi request reprint Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Biochem Biophys Res Commun 334:313-8. 2005
    ..Taken together, IFN-alpha-induced activations of NF-kappaB and COX-2 were inhibited by the addition of curcumin in A549 cells...
  25. ncbi request reprint Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Clin Cancer Res 13:3250-4. 2007
    ..The aim of the study was to determine the effect of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) in bone marrow specimens on survival outcome in patients with clinical stage I/II natural killer/T-cell lymphoma...
  26. ncbi request reprint Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer
    Sarah Park
    Samsung Medical Center, Division of Hematology Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, 50 Ilwon Dong Kangnam Ku, Seoul 135 710, Republic of Korea
    Lung Cancer 58:116-22. 2007
    ..Further studies are warranted to define the effects of PI chemotherapy on quality of life and survival benefits...
  27. doi request reprint The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, Seoul 135 710, Korea
    J Cancer Res Clin Oncol 137:687-94. 2011
    ..We investigated the relationships between the two most common types of somatic EGFR mutations, exon 19 deletions and L858R mutations, and clinical outcomes of Korean NSCLC patients after treatment with gefitinib or erlotinib...
  28. ncbi request reprint Nongastric marginal zone B-cell lymphoma: analysis of 247 cases
    Sung Yong Oh
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Am J Hematol 82:446-52. 2007
    ..NG-MZL is an indolent disease. FLIPI has strong power to predict the prognosis of NG-MZL...
  29. doi request reprint Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group
    Ji Eun Uhm
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 4:1136-43. 2009
    ..The aim of this study conducted by the Korean Cancer Study Group was to evaluate the efficacy and tolerability of erlotinib monotherapy as a palliative treatment for advanced NSCLC patients in Korea...
  30. doi request reprint A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer
    Jun Ho Yi
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Oncology 80:175-80. 2011
    ..Our aim was to devise a prognostic model for advanced pancreatic cancer based on clinical parameters...
  31. ncbi request reprint Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul 135 710, South Korea
    Lung Cancer 69:105-9. 2010
    ..The purpose of this study was to evaluate the accuracy of RECIST 1.1 for non-small cell lung cancer (NSCLC) patients being treated with epidermal growth factor receptor tyrosine kinase inhibitors (TKIs)...
  32. ncbi request reprint Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
    Seung Tae Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer 116:3025-33. 2010
    ..This prompted us to analyze the clinical outcomes between gefitinib-treated and erlotinib-treated patients with metastatic or recurrent NSCLC...
  33. ncbi request reprint A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
    Seung Tai Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Gu, Seoul 135 710, Korea
    Cancer 106:1339-46. 2006
    ..In addition, the correlation between the CA 19-9 response and clinical outcome was analyzed...
  34. pmc FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications
    Kyung Min Shin
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Korean J Radiol 9:481-9. 2008
    ..We aimed to compare the prognoses of patients with pathologically true negative (P-TN) N2 and PET/CT false negative (FN) results in stage T1 non-small cell lung cancer (NSCLC)...
  35. doi request reprint Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment
    Seung Tae Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Oncology 79:78-84. 2010
    ..To devise a prognostic model based on clinical parameters for non-small cell lung cancer (NSCLC) patients treated with erlotinib as a salvage therapy...
  36. doi request reprint Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 5:540-5. 2010
    ..The purpose of this study was to select patients with NSCLC who could most benefit from maintenance therapy, by evaluating which patients would be less likely to receive second-line therapy...
  37. doi request reprint Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery
    Hee Kyung Ahn
    Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Lung Cancer 79:300-6. 2013
    ..Therefore, the role of TKI for adjuvant EGFR TKI to decrease disease recurrence in distant sites should be further investigated...
  38. ncbi request reprint Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen
    Se Hoon Park
    Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Am J Clin Oncol 27:477-80. 2004
    ..Tolerance was acceptable, with the main toxicity being neutropenia. The authors conclude that second-line chemotherapy with docetaxel plus cisplatin for advanced gastric cancer is feasible with an acceptable toxicity level...
  39. ncbi request reprint Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years
    Ji Hye Min
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135 710, Republic of Korea
    Lung Cancer 69:123-6. 2010
    ..In addition, the evolving process of this case may suggest a guideline for planning an appropriate follow-up examination and management in such cases...
  40. doi request reprint Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray
    Hyeong Su Kim
    Division of Hematology and Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Korea
    Cancer 116:676-85. 2010
    ....
  41. ncbi request reprint Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, 135 710 Seoul, Republic of Korea
    Lung Cancer 69:330-6. 2010
    ..We also aimed to evaluate risk factors associated with the development of PE as well as the prognostic power of PE in lung cancer patients...
  42. ncbi request reprint Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 6:1392-9. 2011
    ....
  43. doi request reprint A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors
    Silvia Park
    Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 8:959-66. 2013
    ..Here, we report the results of a prospective study of neoadjuvant docetaxel/cisplatin in locally advanced TETs...
  44. pmc Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy
    Soohyeon Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, Seoul 135 710, Korea
    J Cancer Res Clin Oncol 137:1203-11. 2011
    ..Therefore, it is paramount to delineate the molecular characteristics of this disease entity...
  45. ncbi request reprint Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer
    Sarah Park
    Department of Medicine, Division of Hematology Oncology, Hangang Sacred Heart Hospital, Hallym University School of Medicine, Seoul, Korea
    J Thorac Oncol 4:809-15. 2009
    ..Given the heterogeneity of NSCLC at the molecular level, this study was conducted to determine the discrepancy in EGFR mutations between primary tumors and the corresponding lymph node metastasis...
  46. doi request reprint Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer
    Dae Ho Lee
    Department of Oncology, Asan Medical Center, University of UIsan College of Medicine, Seoul, Korea
    Cancer 116:132-6. 2010
    ..The objective of this study was to investigate the efficacy of belotecan, a new camptothecin analog, combined with cisplatin for the treatment of chemotherapy-naive patients with extensive-disease small cell lung cancer (ED SCLC)...
  47. ncbi request reprint An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach
    Sung Kim
    Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnam Gu, Seoul, South Korea
    Int J Radiat Oncol Biol Phys 63:1279-85. 2005
    ..We investigated the effect of postoperative chemoradiotherapy on the relapse rate and survival rate of patients with D2-resected gastric cancer...
  48. doi request reprint Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy
    Seung Hwan Moon
    Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul 135 710, Republic of Korea
    Eur J Nucl Med Mol Imaging 40:1005-13. 2013
    ....
  49. doi request reprint Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment
    Min Jae Park
    Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer 115:1518-30. 2009
    ..A prognostic model based on clinical parameters for nonsmall cell lung cancer (NSCLC) patients treated with gefitinib (250 mg/day) as a salvage therapy was devised...
  50. ncbi request reprint Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study
    Do Hyoung Lim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnam Ku, Seoul 135 710, Korea
    Cancer Chemother Pharmacol 56:10-4. 2005
    ....
  51. doi request reprint Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma
    Won Seog Kim
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Med Oncol 25:447-50. 2008
    ..Therefore, this organ-preserving combined approach was effective for the maintenance of the QOL and minimization of stomach abnormalities in patients with gastric lymphoma...
  52. ncbi request reprint Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
    Myung Ju Ahn
    Division of Hematology Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    Clin Cancer Res 14:3860-6. 2008
    ..This study investigated possible molecular predictors of outcome in Korean patients with advanced non-small cell lung cancer treated with erlotinib...
  53. ncbi request reprint Postremission therapy for acute myeloid leukemia in the first remission
    Seung Tai Kim
    Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Leuk Lymphoma 48:937-43. 2007
    ..However, there was no difference between allogeneic HSCT and autologous HSCT in terms of EFS and OS. In the intermediate- or low-risk group, there was no significant difference in the outcome according to the postremission modalities...
  54. doi request reprint Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system
    Byung Woo Jhun
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Lung Cancer 81:65-70. 2013
    ..The UICC 7th TNM staging system may contribute to a more precise prognosis in SCLC patients. Further studies are required to evaluate the applicability of the TNM staging system to SCLC...
  55. ncbi request reprint Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
    Byeong Bae Park
    Divisions of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Gu, Seoul 135 710, Republic of Korea
    Lung Cancer 53:323-30. 2006
    ..This study reports efficacy, toxicity and feasibility of neoadjuvant chemotherapy with concurrent radiotherapy (CCRT) in stage IIIA, N2 positive NSCLC...
  56. doi request reprint Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors
    Su Jin Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Thorac Oncol 8:185-91. 2013
    ..The clinical features and prognostic factors of LC in NSCLC patients, however, have not been well identified. The aim of this study was to identify the clinical features and prognostic factors of NSCLC patients with LC...
  57. doi request reprint Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
    Seung Tae Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Lung Cancer 75:82-8. 2012
    ..In this randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib was evaluated as the second-line therapy for advanced non-small cell lung cancer (NSCLC)...
  58. doi request reprint The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma
    Jung Yong Hong
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon dong Kangnam gu, 135 710 Seoul, South Korea
    Med Oncol 26:287-91. 2009
    ..Moreover, additional novel treatment approaches are required...
  59. ncbi request reprint Primary pulmonary non-Hodgkin's lymphoma
    Jung Han Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 135 710 Seoul, Korea
    Jpn J Clin Oncol 34:510-4. 2004
    ..Although there have been a few reviews of this lymphoma, clinical features, diagnostic procedure, optimal management and prognostic factors have not been well defined...
  60. ncbi request reprint High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients
    Chi Hoon Maeng
    Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul 135 710, South Korea
    Anticancer Res 33:5127-33. 2013
    ....
  61. ncbi request reprint Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer
    Jinny Park
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Clin Cancer Res 10:4383-8. 2004
    ..Here we report the outcome of gefitinib therapy in patients who enrolled in the "Iressa" Expanded Access Program at the Samsung Medical Center...
  62. pmc Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer
    Min Kyu Kang
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, Korea
    J Korean Med Sci 21:229-35. 2006
    ....
  63. doi request reprint Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications
    Hyun Jung Yoon
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Ku, Seoul 135 710, Korea
    Radiology 265:939-48. 2012
    ..To evaluate the feasibility and safety of repeat biopsy for mutational analysis in patients with non-small cell lung cancer (NSCLC) who have a resistance history to previous chemotherapy...
  64. doi request reprint Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras
    Hyo Song Kim
    Department of Internal Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Oncology 76:239-46. 2009
    ..The aim of this study was to analyze the survival difference between advanced non-small cell lung cancer (NSCLC) patients in the pre-gefitinib and post-gefitinib eras in Korea...
  65. doi request reprint New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy
    Ho Yun Lee
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135 710, Republic of Korea
    Lung Cancer 73:63-9. 2011
    ..In NSCLC patients treated with EGFR-TKIs, new CT criteria reflecting additional morphological characteristics of target lesions are reproducible and have statistically significant association with overall survival...
  66. doi request reprint Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer
    Myung Hee Chang
    Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    APMIS 117:861-9. 2009
    ..034). These results suggest that IGFR-1 expression may be useful as a prognostic marker in patients with SCLC-ED...
  67. ncbi request reprint The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer
    Myung Hee Chang
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Seoul 135 710, Republic of Korea
    Lung Cancer 69:323-9. 2010
    ..We also analyzed thymidylate synthase (TS) expression in tumor tissues to determine whether TS expression is correlated with the clinical efficacy of pemetrexed...
  68. doi request reprint Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)
    Moon Ki Choi
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul, 135 710, South Korea
    Med Oncol 27:1234-8. 2010
    ..More comprehensive approach to improve the course of ERF and active supportive care, which can prevent complication from leakage, should be developed...
  69. doi request reprint Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications
    Yi Kyung Kim
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Ku, Seoul 135 710, Korea
    Radiology 260:568-74. 2011
    ....
  70. doi request reprint Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases
    Jong Mu Sun
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, Seoul 135 710, Republic of Korea
    Lung Cancer 71:89-93. 2011
    ..Skeletal-related events (SREs) cause significant pain and morbidity to many non-small cell lung cancer (NSCLC) patients. We try to evaluate the predictive factor of SREs in NSCLC patients with bone metastases...
  71. doi request reprint Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Myung Hee Chang
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer 117:143-51. 2011
    ..The objective of the current study was to evaluate the association between AR expression and the efficacy of using EGFR TKIs in the treatment of patients with WT EGFR-positive NSCLC...
  72. doi request reprint Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified"
    Yuna Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Ann Hematol 88:111-9. 2009
    ..1 months (95% CI, 0.0-40.5) and 35.5 months (95% CI, 1.2-69.8), respectively. Poor performance status, the presence of B symptoms, IPI scores >or=3 and PIT class >or=2 were predictive prognostic factors for survival...
  73. ncbi request reprint L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors
    Hyo Song Kim
    Samsung Medical Center, Division of Hematology Oncology, Sungkyunkwan University School of Medicine, 50 Ilwon dong Kangnam gu, Seoul, Korea
    APMIS 117:140-6. 2009
    ..0; 95% confidence interval, 1.2-8.3; p=0.034). L1 expression is significantly associated with aggressiveness and further studies with larger samples are needed to validate potential prognostic value for pulmonary neuroendocrine tumors...
  74. doi request reprint Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
    Ji Hye Min
    Deparment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Cancer Chemother Pharmacol 68:1099-109. 2011
    ..Therefore, familiarity with this complicating ILD is crucial...
  75. doi request reprint Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck
    Jong Mu Sun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Oral Oncol 47:714-9. 2011
    ..017). In conclusion, it is suggested that IGFBP-3 expression, in a state of co-expression with IGF-1R, can predict poor prognosis in SCCHN patients...
  76. doi request reprint The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations
    Myung Ju Ahn
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, Seoul 135 710, Korea
    Hum Genet 131:365-72. 2012
    ..60 × 10(-3) in the validation set) and odds ratio was 0.68 (0.58-0.79). We observed similar association for rs11663246. Our result suggests the 18p11.22 region as a novel lung cancer susceptibility locus in never smokers...
  77. doi request reprint Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer
    Man Ki Chung
    Departments of Otorhinolaryngology Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Clin Cancer Res 15:5861-8. 2009
    ....
  78. pmc Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria
    Ho Yun Lee
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Korean J Radiol 11:618-26. 2010
    ..We wanted to compare the efficacy of the new CT response evaluation criteria for predicting the tumor progression-free survival (PFS) with that of RECIST 1.1 in non-small cell lung cancer (NSCLC) patients who were treated with bevacizumab...
  79. doi request reprint Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit
    Jae Uk Song
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    Support Care Cancer 19:491-5. 2011
    ..Therefore, this study evaluated the outcomes and prognostic factors in critically ill cancer patients receiving chemotherapy in the ICU...
  80. doi request reprint Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats
    Jong Mu Sun
    Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer Chemother Pharmacol 68:531-8. 2011
    ..Leptomeningeal carcinomatosis is a devastating complication of malignant disease. In this study, we evaluated the safety and pharmacokinetics of intrathecally administered pemetrexed in rats...
  81. ncbi request reprint Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer
    Joon Oh Park
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul, Republic of Korea
    J Clin Oncol 25:5233-9. 2007
    ..This trial was conducted to determine the optimal duration of chemotherapy in Korean patients with advanced non-small-cell lung cancer (NSCLC)...
  82. doi request reprint Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity
    Seok Jin Kim
    Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul 135 710, Korea
    Invest New Drugs 30:368-75. 2012
    ..We studied the efficacy and toxicity of combination treatment of alemtuzumab, dexamethasone, cytarabine, and cisplatin (A-DHAP) for treating PTCL...
  83. pmc Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma
    Hyun Jung Jun
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Cancer Res Treat 39:40-3. 2007
    ....
  84. doi request reprint Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma
    Byeong Bae Park
    Division of Hematology Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
    Leuk Lymphoma 49:88-94. 2008
    ..The superior survival outcome for HCV-positive DLBL should be verified by further investigation, especially with respect to its correlation with transformed low-grade NHL...